Mobile

A multicenter trial comparing the efficacy and safety of GSK573719/GW642444 with GSK573719 with tiotropium over 24 weeks in subjects with COPD

Mise à jour : Il y a 4 ans
Référence : EUCTR2010-021802-39

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective is to compare the efficacy of two doses of GSK573719/GW642444 Inhalation Powder (125mcg/25mcg and 62.5/25mcg once-daily) with GSK573719 (125mcg once daily) and with tiotropium (18mcg once-daily) over 24 weeks for the treatment of subjects with COPD.

Critère d'inclusion

  • Chronic Obstructive Pulmonary Disease (COPD)

Liens